SEC Comment Letter 0000000000-23-007304 to ARTELO BIOSCIENCES, INC. (ARTL)
ARTELO BIOSCIENCES, INC.
Date: July 10, 2023 · CIK: 0001621221 · Accession: 0000000000-23-007304
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273153
Letter
United States securities and exchange commission logo July 10, 2023 Gregory Gorgas President and Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, California 92075 Re:Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed July 6, 2023 File No. 333-273153 Dear Gregory Gorgas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tom Hornish
Show Raw Text
United States securities and exchange commission logo
July 10, 2023
Gregory Gorgas
President and Chief Executive Officer
Artelo Biosciences, Inc.
505 Lomas Santa Fe, Suite 160
Solana Beach, California 92075
Re:Artelo Biosciences, Inc.
Registration Statement on Form S-3
Filed July 6, 2023
File No. 333-273153
Dear Gregory Gorgas:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Tom Hornish